Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
EBERHARD KARLS UNIVERSITÄT TÜBINGEN has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 7 distinct examiners and 7 distinct art units, showing that the pending portfolio spans multiple examination channels rather than one centralized assignment.
UNDERDAHL, THANE E is the busiest examiner, with 1 pending matter. No examiner accounts for more than that stated workload, so counsel should organize prosecution review by individual matter, examiner, and art unit.
The matching examiner and art-unit counts indicate that each recorded examination assignment is distinct in both dimensions. A coordinated portfolio process can still standardize disclosure review and claim-support analysis, while leaving response arguments responsive to the applicable examiner and unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| UNDERDAHL, THANE E | 1 | 58.8% | +50.2% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
| XU, QING | 1 | 50.9% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 36d overdue |
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | — |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | — |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | — |
| 17671407 | Method for Classifying a Patient's Responsiveness to Immune Checkpoint Inhibitor Therapy | BELLAH, JEFFREY LAWRENCE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 36d overdue |
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | — |
| 18500468 | METHOD FOR DIAGNOSING A PREDISPOSITION OF A LIVING BEING TO DEVELOP THROMBOCYTOPENIA | KINSEY WHITE, NICOLE ERIN | — |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | — |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1672 | 1 |
| 1636 | 1 |
| 1644 | 1 |
| 1600 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18405956 | COMPOUND AND METHOD FOR AN ALLELE-SPECIFIC EDITING OF THE ELANE GENE | UNDERDAHL, THANE E | 1699 | §102§103§112 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18500468 | METHOD FOR DIAGNOSING A PREDISPOSITION OF A LIVING BEING TO DEVELOP THROMBOCYTOPENIA | KINSEY WHITE, NICOLE ERIN | 1672 | §103 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18453993 | METHOD AND COMPOSITION FOR A TARGETED GENE KNOCKOUT | SU-TOBON, QIWEN NMN | 1636 | §103§112Other | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17671407 | Method for Classifying a Patient's Responsiveness to Immune Checkpoint Inhibitor Therapy | BELLAH, JEFFREY LAWRENCE | 1600 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 14, 2022 |
| 17449723 | COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES | XU, QING | 1656 | §103§112 | Non-Final OA | 36d overdue | Pending | Oct 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEBERHARD KARLS UNIVERSITÄT TÜBINGEN has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Thane E Underdahl has the most, with 1 of EBERHARD KARLS UNIVERSITÄT TÜBINGEN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
